Comparative Pharmacology
Head-to-head clinical analysis: RENO 30 versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENO 30 versus RENOVIST.
RENO-30 vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent